Drug Profile
ra 76
Alternative Names: ra76Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Kao Corporation
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for clinical-Phase-Unknown development in Atopic-dermatitis(Combination therapy) in Japan (Topical, Cream)
- 23 Feb 2022 No development reported - Phase-II for Atopic dermatitis in Japan (Topical)
- 13 Sep 2017 Kao Corporation and Exam CO completes a phase II trial for Atopic dermatitis in Japan (Topical) (UMIN000025722)